Palivizumab
ATC Code
J06BD01
Palivizumab
Definition
A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.
Also known as MEDI 493, PALIVIZUMAB, Synagis — per NCIT
Also identified as
- ATC J06BD01 per RXNORM
- NCIT NCIT:C2625 per NCIT
- SCTID 108725001 per RXNORM
- SCTID 386900007 per RXNORM
- UNII DQ448MW7KS per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Respiratory syncytial virus infectious disease | may prevent | MEDRT · Public domain (U.S. Government work) |